bioMérieux

Equities

BIM

FR0013280286

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:04 2024-04-26 am EDT			5-day change	1st Jan Change
101.5 ^EUR	+2.01%		+1.96%	+0.89%

Apr. 26	BioMérieux: share price rises, analyst remains Buy	CF
Apr. 26	BIOMÉRIEUX : Berenberg raises its target	CF

BioMérieux S.A. acquired remaining 84% stake in Luméd inc.

January 04, 2024

bioMérieux S.A. (ENXTPA:BIM) acquired remaining 84% stake in Luméd inc. for ?9 million on January 5, 2024. bioMérieux has acquired the entire share capital of LUMED, increasing its stake from 16% to 100%.

bioMérieux S.A. (ENXTPA:BIM) completed the acquisition of remaining 84% stake in Luméd inc. on January 5, 2024.

Latest news about bioMérieux

BioMérieux: share price rises, analyst remains Buy	Apr. 26	CF
BIOMÉRIEUX : Berenberg raises its target	Apr. 26	CF
Deutsche Bank Initiates BioMérieux Coverage at Purchase	Apr. 23	MT
BIOMÉRIEUX : Deutsche Bank initiates buy coverage	Apr. 23	CF
BioMérieux: on the rise, Deutsche Bank initiates buy coverage	Apr. 23	CF
Stifel Reaffirms bioMérieux at Buy, Lifts PT	Apr. 10	MT
BIOMÉRIEUX : Stifel raises target price	Apr. 10	CF
Invest Securities Lifts BioMérieux PT, Maintains at Buy	Apr. 10	MT
Oddo BHF Raises bioMérieux PT, Affirms Neutral Recommendation	Apr. 10	MT
BIOMÉRIEUX : Oddo BHF raises its target price	Apr. 10	CF
BIOMÉRIEUX : Invest Securities raises its target	Apr. 10	CF
BIOMERIEUX : A strong start to 2024	Apr. 09
BioMérieux: hailed for its business review and targets	Apr. 09	CF
U.S. Futures Mixed, European Stocks Lower Ahead of U.S. Inflation Data This Week	Apr. 09	DJ
Transcript : BioMérieux S.A. - Analyst/Investor Day	Apr. 09
BioMérieux: targets set for 2024-28	Apr. 09	CF
BioMérieux: growth of over 6% in Q1	Apr. 09	CF
BioMérieux: food safety initiative	Apr. 05	CF
BioMérieux: FDA approval for multiplex PCR test	Mar. 27	CF
Berenberg Upgrades BioMérieux to Buy from Hold, Lifts PT	Mar. 21	MT
BIOMÉRIEUX : Berenberg upgrades its recommendation to 'buy	Mar. 21	CF
BioMérieux: Invest Securities reiterates its opinion	Mar. 15	CF
Invest Securities Keeps BioMérieux at Buy, Reduces PT	Mar. 15	MT
BIOMÉRIEUX : Invest Securities remains positive, reduces its target	Mar. 15	CF
BIOMERIEUX : Good end to 2023; routine testing dynamics remain intact	Mar. 14

Chart bioMérieux

Duration

Period

More charts

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-22 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIOMERIEUX : A strong start to 2024

April 09, 2024 at 10:38 am EDT

More Strategies

Ratings for bioMérieux

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

101.5 EUR

Average target price

112.8 EUR

Spread / Average Target

+11.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.3B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B
MYRIAD GENETICS, INC.	-5.02%	1.64B

Diagnostic & Testing Substances